CA1278242C - Aqueous solution for the urodynamic investigation of the urinary bladder - Google Patents
Aqueous solution for the urodynamic investigation of the urinary bladderInfo
- Publication number
- CA1278242C CA1278242C CA000503515A CA503515A CA1278242C CA 1278242 C CA1278242 C CA 1278242C CA 000503515 A CA000503515 A CA 000503515A CA 503515 A CA503515 A CA 503515A CA 1278242 C CA1278242 C CA 1278242C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- solution
- ion
- water
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003932 urinary bladder Anatomy 0.000 title claims abstract description 36
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 11
- 238000011848 urodynamic investigation Methods 0.000 title claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 44
- 239000000126 substance Substances 0.000 claims abstract description 24
- 210000002700 urine Anatomy 0.000 claims abstract description 16
- 239000000872 buffer Substances 0.000 claims abstract description 9
- 239000003792 electrolyte Substances 0.000 claims abstract description 9
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 9
- 229940037395 electrolytes Drugs 0.000 claims abstract 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 9
- 229940109239 creatinine Drugs 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 7
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 6
- 239000012928 buffer substance Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910001415 sodium ion Inorganic materials 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 239000008139 complexing agent Substances 0.000 claims description 4
- 230000000249 desinfective effect Effects 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 159000000001 potassium salts Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229940085991 phosphate ion Drugs 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 abstract description 6
- 235000010356 sorbitol Nutrition 0.000 description 8
- 229960002920 sorbitol Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 210000003741 urothelium Anatomy 0.000 description 6
- 208000000187 Abnormal Reflex Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 206010020745 hyperreflexia Diseases 0.000 description 4
- 230000035859 hyperreflexia Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 206010003084 Areflexia Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229940003871 calcium ion Drugs 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009975 flexible effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
ABSTRACT
Aqueous solution for the urodynamic investigation of the urinary bladder to diagnose voiding disturbances, which contains 50 - 70 mmol potassium ions per liter, is adjusted to a pH of 4.7 - 5.2 which is stabilized by addi-tion of buffer, and furthermore contains amounts of elec-trolytes normally found in urine, and of water-soluble, stable, low molecular weight organic substances, such that the solution has an osmolarity of 1,000 to 1,360 mosmol/l solution.
Aqueous solution for the urodynamic investigation of the urinary bladder to diagnose voiding disturbances, which contains 50 - 70 mmol potassium ions per liter, is adjusted to a pH of 4.7 - 5.2 which is stabilized by addi-tion of buffer, and furthermore contains amounts of elec-trolytes normally found in urine, and of water-soluble, stable, low molecular weight organic substances, such that the solution has an osmolarity of 1,000 to 1,360 mosmol/l solution.
Description
4;~
Aqueous solution for the urodynamic investigation of the urinary bladder The present invention relates to an aqueous solu-tion for the urodynamic investigation of the urinary blad-der, which is used for the diagnosis of bladder voidingdisturbances.
Such voiding disturbances of the urinary bladder may consist either in areflexia, that is to say even when the urinary bladder is full there is no muscular contrac-tion which result in the urge to urinate, or in a hyper-reflexia of the bladder, which is manifested by a very frequent urge to urinate. It llas been proposed, according to Jonas U. and Thuroff J., Urodynamische Untersuchungen, Urologie in Klinik und Praxis (Urodynamic Investigations,-Clinical and Practical Urology) published by G. Thieme,Stuttgart/New York, 1982, page 254, that, for the diag-nosis of such voiding disturbances by use of commercially available cystometers, the urinary bladder be filled with water, isotonic saline solution or C02, and the volume at which the urge to urinate is triggered be determined.
This ty~e of investigation was based on the doctrine that _ the stimulus to void the bladder is initiated exclusively by neural impulses, it being assumed that the urothelium is impermeable and allows no exchange of matter.
However, this test method has not been satisfactory in practice since it was not possible to detect any void-ing disturbance in a number of patients who complained of symptoms but for whom, nevertheless, it frequently emerged subsequently that there was a urinary bladder disorder.
On the other hand, Fellows G.J. and MarshalL D.H.
have already pointed out, in Invest. Urol. 9, 339, 1972, that under certain conditions the urothelium certainly allows exchange of matter with the blood, with emergence not only of water but also of ions being possible, and this exchange of matter increases further in most dis~
orders of the urinary bladder. Moreover, it has already been observed in animal experiments that potassium can ~P
,,, , ~
8~
Z
bring about contractions of the bladder muscle in pigs (V.
Duyl W.A. and Collsaet B.L.R.A., Urology 20, 53, 198Z).
The present invention has the object of providing a test solution for the urodynamic investigation of the urinary bladder, which allows reliable diagnosis of void~
ing disturbances.
This object is achieved according to the present invention on the basis of the surprising finding that the triggering of the urge to urinate is very greatly deter-mined by the composition of the urine, and the potassiumcontent, pH and osmolarity control the urge to urinate, so that when the urine is concentrated, with, for example, a greatly increased potassium content compared with the blood, and has a high osmolarity, the contraction of the muscles of the urinary bladder, which may be designated the process which effects the voiding of the bladder, is initiated when the volume contained in the bladder is considerably lower than is the case with considerably more dilute urine. Another initiating factor proved to be the Z0 H ion which, up to a certain extent, is able to take the place of the K ion inside the cell.
Thus, a high concentration of K ions and H ions and hyperosmolarity may bring about contraction of the muscles underlying the urothelium without there being neural impulses from the CNS.
Building on this finding, it was found, surpris-ingly, that an aqueous solution for urodynamic investiga-tion of the urinary bladder permits reliable diagnoses of voiding disturbances, namely both areflexia and hyper-reflexia, if its potassium content and osmolarity corres-pond to those of a concentrated urine, and its pH is main-tained constant in the range of an acid urine. A solution of this type reliably brings about early initiation of the urge to urinate for the investigated urinary bladder, so that the figures obtained with it are far more appropriate to the local physiological situation of bladder function than was the case with the previous diagnostic me~hod.
This means that areflexia of the bladder is detected only 7~;~4~
where it actually exists and not in cases where the bladder has a very large capacity for water, and likewise hyper-reflexia, for example caused by increased permeability of the urothelium, is not concealed.
Accordingly, the present invention relates to an aqueous solution for the urodynamic investigation of the human urinary bladder, comprising potassium ions in an amount of 50 - 70 mmol/l, electrolytes which occur in huMan urine, and water-soluble organic substances which are stable in aqueous solution, are tolerated by the human urinary blad-der and do not have a strongly acid or alkaline intrinsic pH, and whose molecular weight is in a range which is suf-ficiently low for them to have osmotic activity, which solution has an osmolarity of 1,000 -1~360 mosmol/l, and a pH of 4.7 - 5.2 which is stabilized by addition of buf-fer substances.
The choice of the concentration, according to the invention, of K ions is based on the usual figures for the concentration of K ions in concentrated urine of around 60 mmol/l, so that the figure according to the invention complies with the physiological condition for early ini-tiation of the urge_to urinate. When setting up the pH
of 4.7 - S.Z, preferably of 5.0, it has to be borne in mind that when the urine present is acid the urinary blad-der attempts to increase the pH by water leaving the cir-culating blood through the urothelium, that is to say that the acid pH would not be maintained during the stay of the test solution in the urinary bladder, especially when the urothelium is highly permeable, and the consequence would be faulty diagnoses. For this reason, it is essential that the solution according to the invention contains buffer substances which bring about the stabilization of the pH in the acid range.
It has to be borne in mind in the selection of low molecular weight, and thus osmotically active, substances, which are used in addition ~o electrolytes to see up the osmolarity which is to be chosen according to the 1;~'78~4;~
invention, that these substances do not decompose in the ueakly acid aqueous solution. Urea, which substantially determines the osmolarity of urine, is not suitable for this purpose because of its instability. Furthermore, S all those substances which, because of a strongly acid or alkaline intrinsic pH, would shift the pH of the solution have also to be excluded, and, finally, substances which affect the activity of the bladder, whether they result in manifestations of irritation or inhibit the activity of the bladder, are also unsuitable. The use of water-soluble polyhydroxy compounds has proved to be very appro-pr;ate, and sugar alcohols such as, in particular, sor-bitol, xylitol and mannitol, glucose and fructose, and glycerol, have proved part;cularly useful. The sugar alcohols sorbitol and mannitol, and glycerol, are pre-ferred in this context, sorbitol being particularly pre-ferred. It is frequently appropriate, especialLy in the case where monosaccharides are used as substances for setting up the osmolarity, to add a small amount of dis-infecting agents to the solution, since these sugars rep-resent nutrients for bacteria and thus, in certain cir-cumstances, in cases of bladder infections contribute to a multiplication of the bacteria which have caused them, and thus might result in a deterioration in the condition of the patient. Mention may be made, as examples of dis-infectants which have proved to be very useful, of benz-alkonium chloride or, especially, the esters-of 4-hydroxy-benzoic acid, which can be used alone or in mixture.
Furthermore, the addition of stabilizing additives, such as antioxidants, has proved useful in some cases, especially when reducing sugars are used as low molecular weight organic substances for setting up the osmolarity.
Examples of these which may be mentioned are sulfites or pyrosulfites.
Apart from the polyhydroxy compounds, which can usually be added in relatively large amounts, for example in amounts of about 100 - 170 g/l of solution, it is also possible to rnake use of, in addition, stable substances ~'~7~3~4~
excreted in the urine, such as, for example, creatinine, to set up the osmolarity required according to the inven-tion.
Since the intention is that the constitution of the solution according to the ;nvent;on be as close as possible to the composition of urine, it has proved appro-priate also to make use of, in addition to the prescribed content of K ions and in addition to low molecular weight organic substances, other electrolytes which normally occur in urine to set up the osmolarity. Water-soluble salts of sodium, calcium and magnesium are primarily used for this, preferably in an amount and composition which is typical of urine. This means that relatively large amounts of sodium salts, for example 2 - 4 times the molar 1S amount relative to the content of potassium salts present, can be used, whereas the appropriate molar amounts of Ca and Mg salts should be only a fraction of the molar amounts of alkal; metal salts present. The salts of potassium and sodium are preferably chlorides and sulfates, whereas cal-cium is preferably used as chloride, and magnesium is usedas chloride and as sulfate.
Since phosphates, for example those of sodium or potassium, are primarily advisa_le as buffer substances, ~ it is appropriate also to add complexing substances such as, for example, salts of ethylenediamineteeraacetic acid - - in order to prevent the formation of a precipitate with Ca and/or Mg ions present.
An aqueous solution which contains the following constituents per liter has proved particularly useful according to the invention:
as cations K ion 50 - 70 mmol Na ion 100 - 140 mmol Ca ion 1.5 - 4 mmol 3S Mg ion 5 - 10 mmol as anions:
chloride 120 - 145 mmol sulfate 10 - 20 mmol ~xt7s~4~
as buffer substance:
phosphate 40 - 65 mmol as water-soluble organic substance:
creatinine 0 - 2~5 9 and sorbitol, mannitol or glycerol in an amount which, together with the other constituents of the solution, results in an osmolarity thereof of 1,000 - 1,360, preferab!y of 1,000 1,300, mosmol/l.
It is appropriate for a small amount of a complex-ing agent and small amounts of disinfecting additives also to be present.
It is particularly preferred in such solutions that the content of potassium ion is 60 - 70 mmol, and that of sodium ion is 125 - 140 mmol, of calcium ion is 2.5 mmol, and of magnesium ion is 7.5 mmol, and that the water-soluble organic substance which is present is sor-bitol in an amount of 120 - 160 9, in each liter, it also being possible for the solution to contain creatinine in ~0 addition~
The pH of` the solution is preferably set at 5.
~ he present invention also relates to an advanta-geous and safe method for the urodynamic investigatiûn of the human urinary bladder with the aid of a commercially available cystometer, in which the solutiorn described above in accordance with the present invention is intro- --duced into the urinary bladder of the patient, and the introduction is continued until the urge to urinate is initiated, whereupon the volume of the solution present in the urinary bladder is determined.
It is possible, using the solution according to the invention, to obtain by this fully reproducible, uni-form test results, so that it is outstandingly suitable for the diagnosis of disturbances of bladder function.
If the figures for the bladder volumes, at which the urge to urinate is initiated, obtained with the solu-tion according to the invention and using a commercially available cystometer (see, for example, Urodynamische ` ~LX~78~4;~
Untersuchungen, published by G. Thieme 1982, pages 254 et seq.) are compared with those attained on filling the urinary bladder with water, it emerges that the figures obtained with water may be up to 80% larger, and thus S existent hyperreflexias are, in certain circumstances, co~pletely masked. The solution according to the inven-tion brings about significantly higher bladder interior pressure amplitudes and affects the sensitivity or urge in the sense of earlier initiation~
For the preparat;on of the solution according to the invention, the electrolytes and/or low molecular weight substances, with the exception of the buffer, in the amount necessary to attain an osmolarity within the l;mit according to the invention, are completely dissolved in approximately the desired amount of water, which is at a temperature of 40 - 80C, it being necessary to bear in mind in apportioning the amount of potassium salts whether the subsequent addition of buffer contains potassium or not. After the pH has been set up, for wh;ch usually an acid is required, it being appropriate for its anion to correspond to the anions present in the solution, the buffer substance is added and thus the pH is stabilized~
The solution is then, where appropriate~ filtered_sterile, where appropriate adjusted to the desired final volume with water for injections, and is sterilized in a custom-ary manne~r.
- For use, it is particularly appropriate to dis-pense the solution according to the invention into flex-ible bags, for example made of P~C. However, glass ves-sels are, of course, also suitable as containers.
In some cases, especially where a long transportroute or maintenance of a relatively large store is en-visaged, it has proved useful to freeze-dry the finished solution according to the invention and to market the lyophilisate. The latter is dissolved in sterile water on the spot before use.
~ 78~4~
Example 1:
897 9 of water for injections at a temperature of 20C are preheated to 60C and, while agitating, 0.37 9 of CaCl2.2 H20~ 0-75 9 of KCl, 1.525 9 of MgCl2.6 H20, 5.5 9 of NaCl, 5.32 9 o~ Na2S04.10 H20, 150 g of sorbito~, 2.2 9 of creatinine, 0.1 9 of ethylenediaminetetraacetic acid disodium salt and, for the purposes of disinfection, 0.15 9 of methyl p-hydroxybenzoate, 0.025 g of ethyl p-hydroxybenzoate and 0.025 9 of propyl p-hydroxybenzoate are added, and mixing is continued until the constituents have completely dissolved. The pH of the solution is then set at S.0 by addition of 0.6 9 of concentrated hydrochlo-ric acid, whereupon 6.8 9 of potassium dihydrogen phosphate are added as buffer substance, and the volume is adjusted to exactly 1 l.
This results in a solution which contains 128 mmol of sod;um ion, 60 mmol of potassium ion, 2.5 mmol of cal-cium ion~ 7.5 mmol of magnesium ion, 132 mmol of chloride ion, 50 mmol of H2P04 ion and 16.5 mmol of sulfate ion, and has an osmolarity of 1,240 mosmol, per liter.
Example 2:
For the preparation of a solution according to _ the invention of approximately the same osmolarity as in Example 1, but not containing creatinine, 0.370 9 of 25 CaCl2.2H20, 0.750 g of KCl, 1.525 9 of MgClz.6H20, 6.250 9 of NaCl, 5.320 9 of Na2S04.10 H20, 150 9 of sorbitol and the complexing agent and the disinfecting additives as in Example 1 are dissolved in preheated water, as described in Example 1, and further processed as in Example 1.
The content of sodium ion in the solution has been increased by this, compared with Example 1, to 140.0 mmol/l, and that of chloride ion to 144.20 mmol/l. The osmolarity of the solution is 1,247 mosmol/l.
Example 3:
The constituents indicated in Example 1, but with the difference that 150 9 of mannitol are used in place of 150 g of sorbitol, are processed to give 1 liter of solution as indicated in Example l. The pH thereof is ~78~
S.0, and the osmolarity is 1,Z40 mosmol/l.
Example 4:
The constituents indicated in Example 1, but with the difference that 76.0 9 of glycerol are used as water-S soluble organic substance in place of sorbitol and crea-tinine, are processed to give 1 liter of solution as in Example 1. The pH of the solution is S.0, and the osmo-larity is 1,Z24 mosmol/l.
Example S:
The constituents mentioned in Example 1, but with the difference that the amount of NaCl used is 5.080 9 and the amount of buffer substance used to increase the buffer capacity is 8.165 9, are processed as described in Example 1 to give l liter of a solution which has the same pH as the solution according to Example 1 and has an osmo-larity of 1,Z27 mosmol/l. Thus, compared with Example 1, tne content of sodium ion was decreased to 1Z0.0 mmol/l, and that of chloride to 124.20 mmol/l, and the phosphate content was increased to 60 mmol/l, and hence the content of potassium ion was increased to 70 mmol/l.
For use, these solutions are filtered sterile, dispensed in 4,500 ml portions into polyvinyl chloride bags and sterili~ed at 115C for S0 minutes. They are completely stable on storage below 20C and can be used as test solution in every commercially available cysto-meter.
Aqueous solution for the urodynamic investigation of the urinary bladder The present invention relates to an aqueous solu-tion for the urodynamic investigation of the urinary blad-der, which is used for the diagnosis of bladder voidingdisturbances.
Such voiding disturbances of the urinary bladder may consist either in areflexia, that is to say even when the urinary bladder is full there is no muscular contrac-tion which result in the urge to urinate, or in a hyper-reflexia of the bladder, which is manifested by a very frequent urge to urinate. It llas been proposed, according to Jonas U. and Thuroff J., Urodynamische Untersuchungen, Urologie in Klinik und Praxis (Urodynamic Investigations,-Clinical and Practical Urology) published by G. Thieme,Stuttgart/New York, 1982, page 254, that, for the diag-nosis of such voiding disturbances by use of commercially available cystometers, the urinary bladder be filled with water, isotonic saline solution or C02, and the volume at which the urge to urinate is triggered be determined.
This ty~e of investigation was based on the doctrine that _ the stimulus to void the bladder is initiated exclusively by neural impulses, it being assumed that the urothelium is impermeable and allows no exchange of matter.
However, this test method has not been satisfactory in practice since it was not possible to detect any void-ing disturbance in a number of patients who complained of symptoms but for whom, nevertheless, it frequently emerged subsequently that there was a urinary bladder disorder.
On the other hand, Fellows G.J. and MarshalL D.H.
have already pointed out, in Invest. Urol. 9, 339, 1972, that under certain conditions the urothelium certainly allows exchange of matter with the blood, with emergence not only of water but also of ions being possible, and this exchange of matter increases further in most dis~
orders of the urinary bladder. Moreover, it has already been observed in animal experiments that potassium can ~P
,,, , ~
8~
Z
bring about contractions of the bladder muscle in pigs (V.
Duyl W.A. and Collsaet B.L.R.A., Urology 20, 53, 198Z).
The present invention has the object of providing a test solution for the urodynamic investigation of the urinary bladder, which allows reliable diagnosis of void~
ing disturbances.
This object is achieved according to the present invention on the basis of the surprising finding that the triggering of the urge to urinate is very greatly deter-mined by the composition of the urine, and the potassiumcontent, pH and osmolarity control the urge to urinate, so that when the urine is concentrated, with, for example, a greatly increased potassium content compared with the blood, and has a high osmolarity, the contraction of the muscles of the urinary bladder, which may be designated the process which effects the voiding of the bladder, is initiated when the volume contained in the bladder is considerably lower than is the case with considerably more dilute urine. Another initiating factor proved to be the Z0 H ion which, up to a certain extent, is able to take the place of the K ion inside the cell.
Thus, a high concentration of K ions and H ions and hyperosmolarity may bring about contraction of the muscles underlying the urothelium without there being neural impulses from the CNS.
Building on this finding, it was found, surpris-ingly, that an aqueous solution for urodynamic investiga-tion of the urinary bladder permits reliable diagnoses of voiding disturbances, namely both areflexia and hyper-reflexia, if its potassium content and osmolarity corres-pond to those of a concentrated urine, and its pH is main-tained constant in the range of an acid urine. A solution of this type reliably brings about early initiation of the urge to urinate for the investigated urinary bladder, so that the figures obtained with it are far more appropriate to the local physiological situation of bladder function than was the case with the previous diagnostic me~hod.
This means that areflexia of the bladder is detected only 7~;~4~
where it actually exists and not in cases where the bladder has a very large capacity for water, and likewise hyper-reflexia, for example caused by increased permeability of the urothelium, is not concealed.
Accordingly, the present invention relates to an aqueous solution for the urodynamic investigation of the human urinary bladder, comprising potassium ions in an amount of 50 - 70 mmol/l, electrolytes which occur in huMan urine, and water-soluble organic substances which are stable in aqueous solution, are tolerated by the human urinary blad-der and do not have a strongly acid or alkaline intrinsic pH, and whose molecular weight is in a range which is suf-ficiently low for them to have osmotic activity, which solution has an osmolarity of 1,000 -1~360 mosmol/l, and a pH of 4.7 - 5.2 which is stabilized by addition of buf-fer substances.
The choice of the concentration, according to the invention, of K ions is based on the usual figures for the concentration of K ions in concentrated urine of around 60 mmol/l, so that the figure according to the invention complies with the physiological condition for early ini-tiation of the urge_to urinate. When setting up the pH
of 4.7 - S.Z, preferably of 5.0, it has to be borne in mind that when the urine present is acid the urinary blad-der attempts to increase the pH by water leaving the cir-culating blood through the urothelium, that is to say that the acid pH would not be maintained during the stay of the test solution in the urinary bladder, especially when the urothelium is highly permeable, and the consequence would be faulty diagnoses. For this reason, it is essential that the solution according to the invention contains buffer substances which bring about the stabilization of the pH in the acid range.
It has to be borne in mind in the selection of low molecular weight, and thus osmotically active, substances, which are used in addition ~o electrolytes to see up the osmolarity which is to be chosen according to the 1;~'78~4;~
invention, that these substances do not decompose in the ueakly acid aqueous solution. Urea, which substantially determines the osmolarity of urine, is not suitable for this purpose because of its instability. Furthermore, S all those substances which, because of a strongly acid or alkaline intrinsic pH, would shift the pH of the solution have also to be excluded, and, finally, substances which affect the activity of the bladder, whether they result in manifestations of irritation or inhibit the activity of the bladder, are also unsuitable. The use of water-soluble polyhydroxy compounds has proved to be very appro-pr;ate, and sugar alcohols such as, in particular, sor-bitol, xylitol and mannitol, glucose and fructose, and glycerol, have proved part;cularly useful. The sugar alcohols sorbitol and mannitol, and glycerol, are pre-ferred in this context, sorbitol being particularly pre-ferred. It is frequently appropriate, especialLy in the case where monosaccharides are used as substances for setting up the osmolarity, to add a small amount of dis-infecting agents to the solution, since these sugars rep-resent nutrients for bacteria and thus, in certain cir-cumstances, in cases of bladder infections contribute to a multiplication of the bacteria which have caused them, and thus might result in a deterioration in the condition of the patient. Mention may be made, as examples of dis-infectants which have proved to be very useful, of benz-alkonium chloride or, especially, the esters-of 4-hydroxy-benzoic acid, which can be used alone or in mixture.
Furthermore, the addition of stabilizing additives, such as antioxidants, has proved useful in some cases, especially when reducing sugars are used as low molecular weight organic substances for setting up the osmolarity.
Examples of these which may be mentioned are sulfites or pyrosulfites.
Apart from the polyhydroxy compounds, which can usually be added in relatively large amounts, for example in amounts of about 100 - 170 g/l of solution, it is also possible to rnake use of, in addition, stable substances ~'~7~3~4~
excreted in the urine, such as, for example, creatinine, to set up the osmolarity required according to the inven-tion.
Since the intention is that the constitution of the solution according to the ;nvent;on be as close as possible to the composition of urine, it has proved appro-priate also to make use of, in addition to the prescribed content of K ions and in addition to low molecular weight organic substances, other electrolytes which normally occur in urine to set up the osmolarity. Water-soluble salts of sodium, calcium and magnesium are primarily used for this, preferably in an amount and composition which is typical of urine. This means that relatively large amounts of sodium salts, for example 2 - 4 times the molar 1S amount relative to the content of potassium salts present, can be used, whereas the appropriate molar amounts of Ca and Mg salts should be only a fraction of the molar amounts of alkal; metal salts present. The salts of potassium and sodium are preferably chlorides and sulfates, whereas cal-cium is preferably used as chloride, and magnesium is usedas chloride and as sulfate.
Since phosphates, for example those of sodium or potassium, are primarily advisa_le as buffer substances, ~ it is appropriate also to add complexing substances such as, for example, salts of ethylenediamineteeraacetic acid - - in order to prevent the formation of a precipitate with Ca and/or Mg ions present.
An aqueous solution which contains the following constituents per liter has proved particularly useful according to the invention:
as cations K ion 50 - 70 mmol Na ion 100 - 140 mmol Ca ion 1.5 - 4 mmol 3S Mg ion 5 - 10 mmol as anions:
chloride 120 - 145 mmol sulfate 10 - 20 mmol ~xt7s~4~
as buffer substance:
phosphate 40 - 65 mmol as water-soluble organic substance:
creatinine 0 - 2~5 9 and sorbitol, mannitol or glycerol in an amount which, together with the other constituents of the solution, results in an osmolarity thereof of 1,000 - 1,360, preferab!y of 1,000 1,300, mosmol/l.
It is appropriate for a small amount of a complex-ing agent and small amounts of disinfecting additives also to be present.
It is particularly preferred in such solutions that the content of potassium ion is 60 - 70 mmol, and that of sodium ion is 125 - 140 mmol, of calcium ion is 2.5 mmol, and of magnesium ion is 7.5 mmol, and that the water-soluble organic substance which is present is sor-bitol in an amount of 120 - 160 9, in each liter, it also being possible for the solution to contain creatinine in ~0 addition~
The pH of` the solution is preferably set at 5.
~ he present invention also relates to an advanta-geous and safe method for the urodynamic investigatiûn of the human urinary bladder with the aid of a commercially available cystometer, in which the solutiorn described above in accordance with the present invention is intro- --duced into the urinary bladder of the patient, and the introduction is continued until the urge to urinate is initiated, whereupon the volume of the solution present in the urinary bladder is determined.
It is possible, using the solution according to the invention, to obtain by this fully reproducible, uni-form test results, so that it is outstandingly suitable for the diagnosis of disturbances of bladder function.
If the figures for the bladder volumes, at which the urge to urinate is initiated, obtained with the solu-tion according to the invention and using a commercially available cystometer (see, for example, Urodynamische ` ~LX~78~4;~
Untersuchungen, published by G. Thieme 1982, pages 254 et seq.) are compared with those attained on filling the urinary bladder with water, it emerges that the figures obtained with water may be up to 80% larger, and thus S existent hyperreflexias are, in certain circumstances, co~pletely masked. The solution according to the inven-tion brings about significantly higher bladder interior pressure amplitudes and affects the sensitivity or urge in the sense of earlier initiation~
For the preparat;on of the solution according to the invention, the electrolytes and/or low molecular weight substances, with the exception of the buffer, in the amount necessary to attain an osmolarity within the l;mit according to the invention, are completely dissolved in approximately the desired amount of water, which is at a temperature of 40 - 80C, it being necessary to bear in mind in apportioning the amount of potassium salts whether the subsequent addition of buffer contains potassium or not. After the pH has been set up, for wh;ch usually an acid is required, it being appropriate for its anion to correspond to the anions present in the solution, the buffer substance is added and thus the pH is stabilized~
The solution is then, where appropriate~ filtered_sterile, where appropriate adjusted to the desired final volume with water for injections, and is sterilized in a custom-ary manne~r.
- For use, it is particularly appropriate to dis-pense the solution according to the invention into flex-ible bags, for example made of P~C. However, glass ves-sels are, of course, also suitable as containers.
In some cases, especially where a long transportroute or maintenance of a relatively large store is en-visaged, it has proved useful to freeze-dry the finished solution according to the invention and to market the lyophilisate. The latter is dissolved in sterile water on the spot before use.
~ 78~4~
Example 1:
897 9 of water for injections at a temperature of 20C are preheated to 60C and, while agitating, 0.37 9 of CaCl2.2 H20~ 0-75 9 of KCl, 1.525 9 of MgCl2.6 H20, 5.5 9 of NaCl, 5.32 9 o~ Na2S04.10 H20, 150 g of sorbito~, 2.2 9 of creatinine, 0.1 9 of ethylenediaminetetraacetic acid disodium salt and, for the purposes of disinfection, 0.15 9 of methyl p-hydroxybenzoate, 0.025 g of ethyl p-hydroxybenzoate and 0.025 9 of propyl p-hydroxybenzoate are added, and mixing is continued until the constituents have completely dissolved. The pH of the solution is then set at S.0 by addition of 0.6 9 of concentrated hydrochlo-ric acid, whereupon 6.8 9 of potassium dihydrogen phosphate are added as buffer substance, and the volume is adjusted to exactly 1 l.
This results in a solution which contains 128 mmol of sod;um ion, 60 mmol of potassium ion, 2.5 mmol of cal-cium ion~ 7.5 mmol of magnesium ion, 132 mmol of chloride ion, 50 mmol of H2P04 ion and 16.5 mmol of sulfate ion, and has an osmolarity of 1,240 mosmol, per liter.
Example 2:
For the preparation of a solution according to _ the invention of approximately the same osmolarity as in Example 1, but not containing creatinine, 0.370 9 of 25 CaCl2.2H20, 0.750 g of KCl, 1.525 9 of MgClz.6H20, 6.250 9 of NaCl, 5.320 9 of Na2S04.10 H20, 150 9 of sorbitol and the complexing agent and the disinfecting additives as in Example 1 are dissolved in preheated water, as described in Example 1, and further processed as in Example 1.
The content of sodium ion in the solution has been increased by this, compared with Example 1, to 140.0 mmol/l, and that of chloride ion to 144.20 mmol/l. The osmolarity of the solution is 1,247 mosmol/l.
Example 3:
The constituents indicated in Example 1, but with the difference that 150 9 of mannitol are used in place of 150 g of sorbitol, are processed to give 1 liter of solution as indicated in Example l. The pH thereof is ~78~
S.0, and the osmolarity is 1,Z40 mosmol/l.
Example 4:
The constituents indicated in Example 1, but with the difference that 76.0 9 of glycerol are used as water-S soluble organic substance in place of sorbitol and crea-tinine, are processed to give 1 liter of solution as in Example 1. The pH of the solution is S.0, and the osmo-larity is 1,Z24 mosmol/l.
Example S:
The constituents mentioned in Example 1, but with the difference that the amount of NaCl used is 5.080 9 and the amount of buffer substance used to increase the buffer capacity is 8.165 9, are processed as described in Example 1 to give l liter of a solution which has the same pH as the solution according to Example 1 and has an osmo-larity of 1,Z27 mosmol/l. Thus, compared with Example 1, tne content of sodium ion was decreased to 1Z0.0 mmol/l, and that of chloride to 124.20 mmol/l, and the phosphate content was increased to 60 mmol/l, and hence the content of potassium ion was increased to 70 mmol/l.
For use, these solutions are filtered sterile, dispensed in 4,500 ml portions into polyvinyl chloride bags and sterili~ed at 115C for S0 minutes. They are completely stable on storage below 20C and can be used as test solution in every commercially available cysto-meter.
Claims (6)
1. Aqueous solution for the urodynamic investigation of the human urinary bladder, comprising potassium ions in an amount of 50 - 70 mmol/l, electrolytes which occur in human urine, and water-soluble organic substances which are stable in aqueous solution, are tolerated by the human urinary blad-der and do not have a strongly acid or alkaline intrinsic pH, and whose molecular weight is in a range which is suf-ficiently low for them to have osmotic activity, which solution has an osmolarity of 1,000 -1,360 mosmol/l, and a pH of 4.7 - 5.2 which is stabilized by addition of buffer substances.
2. Solution as claimed in claim 1, in which the elec-trolytes are salts of Na, Ca and Mg, which are present in a composition and in an amount which are typical of urine.
3. Solution as claimed in claim 1, in which the water-soluble organic substances are one or more compounds selec-ted from the group consisting of sugar alcohols, glucose, fructose, glycerol and creatinine.
4. Solution as claimed in claim 1, containing per Liter 50 - 70 mmol of potassium ion as the electrolytes 100 - 140 mmol of sodium ion 1.5 - 4 mmol of calcium ion
5 - 10 mmol of magnesium ion as cations and 120 - 145 mmol of chloride ion 10 - 20 mmol of sulfate ion as anions, 40 - 60 mmol of phosphate ion as the buffer, as the water-soluble organic substances creatinine in an amount of 0 - 2.5 g, and sorbitol, mannitol or glycerol in an amount which, together with the other constituents of the solution, results in an osmolarity thereof of 1,000 - 1,300 mosmol/l, a complexing agent in an amount which is sufficient to prevent precipitation of Ca and Mg phosphate, and disin-fecting additives.
5. Solution as claimed in claim 4, containing 60 -70 mmol of Potassium ion, as the cations 125 - 140 mmol of sodium ion, 2.5 mmol of calcium ion and 7.5 mmol of magnesium ion, and as the water-soluble organic substances in addition to the 0 - 2.5 g of creatinine 120 - 160 g of sorbitol per liter.
5. Solution as claimed in claim 4, containing 60 -70 mmol of Potassium ion, as the cations 125 - 140 mmol of sodium ion, 2.5 mmol of calcium ion and 7.5 mmol of magnesium ion, and as the water-soluble organic substances in addition to the 0 - 2.5 g of creatinine 120 - 160 g of sorbitol per liter.
6. Process for the preparation of the solution as claimed in claim 1 , which comprises the electro-lytes, the low molecular weight organic substances which are used to set up the osmolarity, and, where appropriate, complexing agents, stabilizers and disinfecting additives being dissolved in approximately the desired amount of water which has been preheated to 40 - 80°C, the pH of the resulting solution being set at a figure of 4.7 - 5.2 by addition of acid, and being stabilized by addition of a buffer substance, the amount of potassium salts to be dissolved in water being apportioned so that, together with K ion which is, where appropriate, contained in the buffer substance, the resulting content of potassium ion is 50 - 70 mmol per liter of solution, whereupon the solu-tion is made up to the desired volume, where appropriate, by addition of water for injections, and is sterilized in the customary manner.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853510115 DE3510115A1 (en) | 1985-03-20 | 1985-03-20 | AQUEOUS SOLUTION FOR URODYNAMIC EXAMINATION OF THE URBAN BLADDER AND METHOD FOR THE PRODUCTION THEREOF |
| DEP3510115.6 | 1985-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1278242C true CA1278242C (en) | 1990-12-27 |
Family
ID=6265831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000503515A Expired - Fee Related CA1278242C (en) | 1985-03-20 | 1986-03-07 | Aqueous solution for the urodynamic investigation of the urinary bladder |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0195354A3 (en) |
| JP (1) | JPS61215332A (en) |
| CA (1) | CA1278242C (en) |
| DE (1) | DE3510115A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2602678B1 (en) * | 1986-08-13 | 1992-06-05 | Drouault Guy | AQUEOUS PHARMACEUTICAL COMPOSITION BASED ON MAGNESIUM, SODIUM AND POTASSIUM SALTS FOR THE REGULATION OF LOCAL CIRCULATIONS |
-
1985
- 1985-03-20 DE DE19853510115 patent/DE3510115A1/en not_active Withdrawn
-
1986
- 1986-03-07 CA CA000503515A patent/CA1278242C/en not_active Expired - Fee Related
- 1986-03-11 EP EP86103249A patent/EP0195354A3/en not_active Withdrawn
- 1986-03-20 JP JP61061040A patent/JPS61215332A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0195354A2 (en) | 1986-09-24 |
| EP0195354A3 (en) | 1989-06-28 |
| DE3510115A1 (en) | 1986-09-25 |
| JPS61215332A (en) | 1986-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Widrow et al. | The effect of parathyroid extract on renal tubular calcium reabsorption in the dog | |
| EP0399549B1 (en) | Hydrous concentrate containing sodium bicarbonate and CAPD-bag system with two chambers | |
| Purkerson et al. | On the influence of extracellular fluid volume expansion on bicarbonate reabsorption in the rat | |
| JP2540101B2 (en) | Dialysate for peritoneal dialysis | |
| Shackney et al. | Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia: report of two cases | |
| Holmberg | Congenital chloride diarrhoea | |
| DE3686718T2 (en) | LIQUID THERAPY WITH 1-LACTATE AND / OR PYRUVATE ANIONS. | |
| Cannon et al. | Methylenebutyryl phenoxyacetic acid: Novel and potent natriuretic and diuretic agent | |
| Walser et al. | Ion association. III. The effect of sulfate infusion on calcium excretion | |
| US20040121982A1 (en) | Biocompatible dialysis fluids containing icodextrins | |
| EP0437274B1 (en) | Bicarbonate and calcium containing infusion and dialysis solution | |
| Arruda et al. | Factors influencing the formation of urinary carbon dioxide tension | |
| Møller et al. | The Syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis? How strong is the evidence? | |
| Perez et al. | Incomplete syndrome of renal tubular acidosis induced by lithium carbonate | |
| Holmberg et al. | The renal lesion in congenital chloride diarrhea | |
| Hagstam et al. | Mannitol infusion in regular haemodialysis treatment for chronic renal insufficiency | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| Mudge et al. | Response to mercurial diuretics during alkalosis: A comparison of acute metabolic and chronic hypokalemic alkalosis in the dog | |
| Konnak et al. | Renal calculi associated with incomplete distal renal tubular acidosis | |
| Labato | Strategies for management of acute renal failure | |
| CA1278242C (en) | Aqueous solution for the urodynamic investigation of the urinary bladder | |
| Kageyama et al. | Effect of insulin on sodium reabsorption in hypertensive patients | |
| Cheng et al. | Potassium wasting and other renal tubular defects with rifampin nephrotoxicity | |
| JP3572085B2 (en) | Nutritional infusion | |
| Johny et al. | Amiloride hydrochloride, a hypercalciuric diuretic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |